Holen Sie sich die Stockscreener-App
2.2099
3.86%
-0.0887
Schlusskurs vom Vortag:
$2.2986
Offen:
$2.2099
24-Stunden-Volumen:
4,271
Relative Volume:
0.54
Marktkapitalisierung:
$3.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.22M
KGV:
-0.2968
EPS:
-7.4459
Netto-Cashflow:
$-4.78M
1W Leistung:
-0.45%
1M Leistung:
+5.44%
6M Leistung:
-15.00%
1J Leistung:
-54.25%
1-Tages-Spanne:
$2.2099
$2.2099
1-Wochen-Bereich:
$2.15
$2.3978
52-Wochen-Spanne:
$1.84
$5.05
Synaptogenix Inc Stock (SNPX) Company Profile
Firmenname
Synaptogenix Inc
Sektor
Branche
Telefon
(973) 242-0005
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Vergleichen Sie SNPX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNPX
Synaptogenix Inc
|
2.2099 | 3.09M | 0 | -8.22M | -4.78M | -7.4459 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Synaptogenix Inc Aktie (SNPX) Neueste Nachrichten
Geode Capital Management LLC Takes $39,000 Position in Synaptogenix, Inc. (NASDAQ:SNPX) - Defense World
Synaptogenix stock plunges to 52-week low of $2.14 By Investing.com - Investing.com Canada
Synaptogenix stock plunges to 52-week low of $2.14 - Investing.com Australia
Synaptogenix Inc. (SNPX) reports earnings - qz.com
Will Synaptogenix Make A Mark In Synaptic Regeneration? - RTTNews
Synaptogenix stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia
Synaptogenix stock hits 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Synaptogenix (NASDAQ:SNPX) Trading Down 0.3% – Here’s Why - Defense World
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18% - MSN
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Synaptogenix Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - Marketscreener.com
Synaptogenix (SNPX) Extends CEO’s Employment and Forms Special Committee to Explore Strategic Opportunities - Defense World
Synaptogenix forms committee to explore strategic opportunities - Investing.com
Synaptogenix forms committee to explore strategic opportunities By Investing.com - Investing.com South Africa
Synaptogenix Restructures Leadership Amid Strategic Refocus - TipRanks
Synaptogenix Forms Special Committee to Explore Strategic Options with $19.6M Cash Runway - StockTitan
Synaptogenix shareholders approve key proposals at annual meeting - Investing.com India
Synaptogenix shareholders approve key proposals at annual meeting By Investing.com - Investing.com Canada
Synaptogenix stock hits 52-week low at $2.71 amid market challenges - Investing.com UK
Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Polyrizon Stock Price, Quotes and Forecasts | NASDAQ:PLRZ - Benzinga
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
Synaptogenix announces reverse stock split to regain Nasdaq compliance By Investing.com - Investing.com South Africa
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. - mg Magazine
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The TechnionIsrael Institute of Technology - PR Newswire
'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial - OutSourcing-Pharma.com
Advanced Alzheimer's: Bryostatin-1 may be safe, effective - Medical News Today
Bryostatin found to slow cognitive decline in advanced Alzheimer's... - Alzheimer's News Today
Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the MarketAzafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, IntraBio Inc, Mandos Health - PR Newswire
Best Penny Stocks To Buy Now? 10 Under $1 To Watch - Penny Stocks
Phase 1 trial of bryostatin-1 in MS expected by year's end |... - Multiple Sclerosis News Today
Oblong Appoints Two New Directors to its Board - Business Wire
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix reports data from Phase II Alzheimer’s trial - Clinical Trials Arena
Synaptogenix's Alzheimer's prospect flops in NIH-sponsored study, sinking stock - Fierce Biotech
Theriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News Summary - Benzinga
Roche's drug failure extends long list of Alzheimer's trial setbacks - Reuters.com
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital - Business Wire
Synaptogenix Announces Corporate Update Conference Call - StockTitan
Synaptogenix Inc (NASDAQ: SNPX) Announces a Peer-reviewed Paper on Bryostatin - BP Journal
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment - Seeking Alpha
Allarity Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ALLR - Benzinga
Quoin Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:QNRX - Benzinga
Finanzdaten der Synaptogenix Inc-Aktie (SNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
6.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):